All In Biotech

Drug Trial Radar · NCT04608318

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

A Phase 3 Multicentre, Randomized, Prospective, Open-label Trial of Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 897 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

897

Planned (sponsor's estimate)

Start

Mar 1, 2021

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
German CLL Study GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Stichting Hemato-Oncologie voor Volwassenen Nederland; Nordic CLL Study Group; Swiss Group for Clinical Cancer Research (SAKK); Cancer Trials Ireland; Gruppo Italiano Malattie EMatologiche dell'Adulto; Grupo Español de Leucemia Linfocítica Crónica (GELLC); The Israeli CLL Study Group (ICLLSG); Janssen Pharmaceutica N.V., Belgium; AbbVie; Hoffmann-La Roche
First posted
Oct 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring progression-free survival (PFS) in patients with previously untreated CLL.

Conditions

  • Chronic Lymphoid Leukemia

Interventions

  • IbrutinibBiological

    Cycles 1 - X: 420 mg daily, d1-28 p.o.

  • VenetoclaxBiological

    Arm VG Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o. Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o. Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o. Arm VI Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o. Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o.

  • ObinutuzumabBiological

    Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed progression-free survival (PFS)Time frame: Up to 80 month

Locations

181 sites in 13 countries. Site status is shown where the registry gives one.

  • LKH-Universtitätsklinikum Graz

    Graz, Austria

  • Landeskrankenhaus - Universitätskliniken Innsbruck

    Innsbruck, Austria

  • Medizinische Universität Wien

    Vienna, Austria

  • Hanusch Krankenhaus

    Vienna, Austria

  • Wiener Gesundheitsverbund Klinik Ottakring

    Vienna, Austria

  • Algemeen Ziekenhuis St. Jan

    Bruges, Belgium

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium

  • Algemeen Ziekenhuis Delta

    Roeselare, Belgium

  • Aalborg Universitetshospital

    Aalborg, Denmark

  • Aarhus Universitetshospital

    Aarhus, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Sydvestjysk Sygehus Esbjerg

    Esbjerg, Denmark

  • Regionshospitalet Holstebro

    Holstebro, Denmark

  • Odense Universitetshospital

    Odense, Denmark

  • Zealand University Hospital

    Roskilde, Denmark

  • Lillebaelt Vejle Sygehus

    Vejle, Denmark

  • Helsinki University Hospital

    Helsinki, Finland

  • Tampere University Hospital

    Tampere, Finland

  • Turku University Hospital

    Turku, Finland

  • Universitätsklinikum Augsburg

    Augsburg, Germany

  • Onkologische Schwerpunktpraxis Kurfürstendamm

    Berlin, Germany

  • Charite Universitaetsmedizin - Campus Benjamin Franklin

    Berlin, Germany

  • Helios Klinikum Berlin Buch

    Berlin, Germany

  • Charite Universitätsmedizin - Campus Virchow Klinikum

    Berlin, Germany

  • Ev. Diakoniekrankenhaus

    Bremen, Germany

  • Universitätsklinik Köln

    Cologne, Germany

  • Gemeinschaftspraxis für Hämatologie & Onkologie

    Dortmund, Germany

  • Gemeinschaftspraxis Hämatologie Onkologie

    Dresden, Germany

  • Universitätsklinik Carl Gustav Carus

    Dresden, Germany

  • Sana Krankenhaus Benrath

    Düsseldorf, Germany

  • St. Georg Klinikum Eisenach

    Eisenach, Germany

  • ISP Erlangen Onkologische Schwerpunktpraxis

    Erlangen, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitaetsklinikum Essen

    Essen, Germany

  • Onkologische Schwerpunktpraxis

    Esslingen am Neckar, Germany

  • Centrum für Hämatologie und Onkologie Bethanien

    Frankfurt, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Uniklinikum Gießen und Marburg

    Giessen, Germany

  • MVZ Onkologische Kooperation Harz

    Goslar, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.